Literature DB >> 21184265

Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.

Amanda I Phipps1, Diana S M Buist, Kathleen E Malone, William E Barlow, Peggy L Porter, Karla Kerlikowske, Christopher I Li.   

Abstract

Breast cancer subtypes defined by estrogen receptor (ER), progesterone receptor (PR), and HER2 expression are biologically distinct and thus, may have distinct etiologies. In particular, it is plausible that risk factors operating through hormonal mechanisms are differentially related to risk of such tumor subtypes. Using data from the Breast Cancer Surveillance Consortium, we explored associations between reproductive history and three breast cancer subtypes. Data on parity and age at first birth were collected from 743,623 women, 10,896 of whom were subsequently diagnosed with breast cancer. Cases were classified into three subtypes based on tumor maker expression: (1) ER positive (ER+, N = 8,203), (2) ER negative/PR negative/HER2 positive (ER-/PR-/HER2+, N = 288), or (3) ER-, PR-, and HER2-negative (triple-negative, N = 645). Associations with reproductive history, evaluated using Cox regression, differed significantly across tumor subtypes. Nulliparity was most strongly associated with risk of ER+ breast cancer [hazard ratio (HR) = 1.31, 95% confidence interval (CI): 1.23-1.39]; late age at first birth was most strongly associated with risk of ER-/PR-/HER2+ disease (HR = 1.83, 95% CI: 1.31-2.56). Neither parity nor age at first birth was associated with triple-negative breast cancer. In contrast to ER+ and ER-/PR-/HER2+ subtypes, reproductive history does not appear to be a risk factor for triple-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21184265      PMCID: PMC3042513          DOI: 10.1007/s10552-010-9709-0

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  24 in total

1.  Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database.

Authors:  R Ballard-Barbash; S H Taplin; B C Yankaskas; V L Ernster; R D Rosenberg; P A Carney; W E Barlow; B M Geller; K Kerlikowske; B K Edwards; C F Lynch; N Urban; C A Chrvala; C R Key; S P Poplack; J K Worden; L G Kessler
Journal:  AJR Am J Roentgenol       Date:  1997-10       Impact factor: 3.959

2.  Differentiation and breast cancer.

Authors:  J Russo; I H Russo
Journal:  Medicina (B Aires)       Date:  1997       Impact factor: 0.653

3.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Authors:  Mi-Jung Kim; Jae Y Ro; Sei-Hyun Ahn; Hak Hee Kim; Sung-Bae Kim; Gyungyub Gong
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

Review 4.  Reproductive factors and breast cancer.

Authors:  J L Kelsey; M D Gammon; E M John
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 6.  Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.

Authors:  Therese Sørlie
Journal:  Eur J Cancer       Date:  2004-12       Impact factor: 9.162

7.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

Review 8.  Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.

Authors:  Michelle D Althuis; Jennifer H Fergenbaum; Montserrat Garcia-Closas; Louise A Brinton; M Patricia Madigan; Mark E Sherman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-10       Impact factor: 4.254

9.  Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there?

Authors:  J D Potter; J R Cerhan; T A Sellers; P G McGovern; C Drinkard; L R Kushi; A R Folsom
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-06       Impact factor: 4.254

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  31 in total

1.  Mammographic density, MRI background parenchymal enhancement and breast cancer risk.

Authors:  M C Pike; C L Pearce
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976

2.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

Authors:  Eunjung Lee; Roberta McKean-Cowdin; Huiyan Ma; Darcy V Spicer; David Van Den Berg; Leslie Bernstein; Giske Ursin
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

3.  Breast cancer subtypes and previously established genetic risk factors: a bayesian approach.

Authors:  Katie M O'Brien; Stephen R Cole; Lawrence S Engel; Jeannette T Bensen; Charles Poole; Amy H Herring; Robert C Millikan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-31       Impact factor: 4.254

4.  Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?

Authors:  Debarshi Jana; Diptendra Kumar Sarkar; Suvro Ganguly; Abhirup Banerjee; Asim Kumar Manna; Syamsundar Mandal
Journal:  Indian J Surg Oncol       Date:  2014-04-06

5.  p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis.

Authors:  A R Yallowitz; E M Alexandrova; F Talos; S Xu; N D Marchenko; U M Moll
Journal:  Cell Death Differ       Date:  2014-01-17       Impact factor: 15.828

6.  Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies.

Authors:  Brian L Sprague; Ronald E Gangnon; John M Hampton; Kathleen M Egan; Linda J Titus; Karla Kerlikowske; Patrick L Remington; Polly A Newcomb; Amy Trentham-Dietz
Journal:  Am J Epidemiol       Date:  2015-05-05       Impact factor: 4.897

7.  Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.

Authors:  Mesut Öztürk; Ahmet Veysel Polat; Yurdanur Süllü; Leman Tomak; Ayfer Kamalı Polat
Journal:  J Breast Health       Date:  2017-01-01

8.  Reproductive factors, heterogeneity, and breast tumor subtypes in women of mexican descent.

Authors:  Maria Elena Martinez; Betsy C Wertheim; Loki Natarajan; Richard Schwab; Melissa Bondy; Adrian Daneri-Navarro; Maria Mercedes Meza-Montenegro; Luis Enrique Gutierrez-Millan; Abenaa Brewster; Ian K Komenaka; Patricia A Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-15       Impact factor: 4.254

9.  Epidemiology of triple negative breast cancers.

Authors:  Gretchen L Gierach; Aileen Burke; William F Anderson
Journal:  Breast Dis       Date:  2010

10.  Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.

Authors:  Carol Sweeney; Philip S Bernard; Rachel E Factor; Marilyn L Kwan; Laurel A Habel; Charles P Quesenberry; Kaylynn Shakespear; Erin K Weltzien; Inge J Stijleman; Carole A Davis; Mark T W Ebbert; Adrienne Castillo; Lawrence H Kushi; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.